HRS4R
Vull donar

ELISABET CUYÀS NAVARRO

Firma
ELISABET CUYÀS-NAVARRO
Posició
Investigador/a Consolidat - R3
Investigador/a Consolidat - R3

Projectes

Codi oficial: CP20/00003 Data inici: 01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: PI22/00297 Data inici: 01/01/2023 Data fi: 31/12/2025 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ, ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: PID2022-141955OB-I00 Data inici: 01/09/2023 Data fi: 31/08/2026 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA E INNOVACION
Codi oficial: FI23/00043 Data inici: 01/01/2024 Data fi: 31/12/2027 Investigador/a principal: ELISABET CUYÀS NAVARRO, JÚLIA LÓPEZ ROMERO Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Steen TV, Espinoza I, Duran C, Casadevall G, Serrano-Hervás E, Cuyàs E, Verdura S, Kemble G, Kaufmann SH, McWilliams R, Osuna S, Billadeau DD, Menendez JA, Lupu R

Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer.

NEOPLASIA, 2025, 62, 101143-101143 dx.doi.org/10.1016/j.neo.2025.101143
López, J, Llop-Hernández, A, Verdura, S, Serrano-Hervás, E, Martinez-Balibrea, E, Bosch-Barrera, J, Teixidor, E, López-Bonet, E, Martin-Castillo, B, Sardanyés, J, Alarcón, T, Lupu, R, Cuyàs, E, Menendez, JA

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

Cell Death Discovery, 2025, 11, 91-91 dx.doi.org/10.1038/s41420-025-02379-y
Espín, R, Medina-Jover, F, Sigüenza-Andrade, J, Farran-Matas, S, Mateo, FSigüenza, Figueras, A, Sanz, RT, Vicent, GP, Shabbir, A, Ruiz-Auladell, L, Racionero-Andrés, E, García, I, Baiges, A, Franco-Luzón, L, Martínez-Tebar, A, Pardo-Cea, MA, Martínez-Iniesta, M, Wang, XC, Cuyàs, E, Menendez, JA, Lopez-Cerda, M, Muñoz, P, Richaud, I, Raya, A, Fabregat, I, Villanueva, A, Serrat, X, Cerón, J, Alemany, M, Guix, I, Herencia-Ropero, A, Serra, V, Krishnan, R, Mekhail, K, Hakem, R, Bruna, J, Barcellos-Hoff, MH, Viñals, F, Aytes, A, Pujana, MA

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment

Nar Cancer, 2025, 7 dx.doi.org/10.1093/narcan/zcaf007
Menendez JA, Cuyàs E, Encinar JA, Steen TV, Verdura S, Llop-Hernández À, López J, Serrano-Hervás E, Osuna S, Martin-Castillo B, Lupu R

Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

MOLECULAR ONCOLOGY, 2024, 18, 479-516 dx.doi.org/10.1002/1878-0261.13582
Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493
Cuyàs E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Hervás E, Llop-Hernández À, Teixidor E, Bosch-Barrera J, López-Bonet E, Martin-Castillo B, Lupu R, Pujana MA, Sardanyès J, Alarcón T, Menendez JA

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Cell Death Discovery, 2024, 10, 417-417 dx.doi.org/10.1038/s41420-024-02184-z
Teixidor-Vilà, E, Verdura, S, JA Encinar, Llop-Hernández À, Sais, E, Hernández Martínez A, ROMERA, A., Brunet JM, Martin-Castillo B, Lopez-Bonet, E, Bosch-Barrera, J, Cuyàs, E, Menendez, JA

1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy

ANNALS OF ONCOLOGY, 2024, 35, 697-697 dx.doi.org/10.1016/j.annonc.2024.08.1097
Cuyàs, E, Verdura, S, Martin-Castillo, B, Menendez, JA

Circulating levels of MOTS-c in patients with breast cancer treated with metformin

Aging-Us, 2023, 15, 892-897
Bosch-Barrera, J, Teixidor, E, Sanvisens, A, Puigdemont, M, Trallero, J, Vila, AV, Osca, G, Roberte, MV, Priego, N, Sais, E, Martínez, AH, Ortega, JS, Cuyàs, E, Verdura, S, Puig, J, Pineda, V, Martí-Navas, M, Calvo, A, Menendez, JA, Marcos-Gragera, R, Valiente, M

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

JOURNAL OF THORACIC ONCOLOGY, 2023, 18, 426-427
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Formulari de contacte

Coneix l’IDIBGI!

menu